Luisa Sophie Schneider, Silka Dawn Freiesleben, Gerard van Breukelen, Xiao Wang, Frederic Brosseron, Michael T. Heneka, Stefan Teipel, Luca Kleineidam, Melina Stark, Nina Roy-Kluth, Michael Wagner, Annika Spottke, Matthias Schmid, Sandra Roeske, Christoph Laske, Matthias H. Munk, Robert Perneczky, Boris-Stephan Rauchmann, Katharina Buerger, Daniel Janowitz, Emrah Düzel, Wenzel Glanz, Frank Jessen, Ayda Rostamzadeh, Jens Wiltfang, Claudia Bartels, Ingo Kilimann, Anja Schneider, Klaus Fliessbach, Josef Priller, Eike Jakob Spruth, Julian Hellmann-Regen, Oliver Peters
{"title":"Linking higher amyloid beta 1-38 (Aβ(1-38)) levels to reduced Alzheimer's disease progression risk","authors":"Luisa Sophie Schneider, Silka Dawn Freiesleben, Gerard van Breukelen, Xiao Wang, Frederic Brosseron, Michael T. Heneka, Stefan Teipel, Luca Kleineidam, Melina Stark, Nina Roy-Kluth, Michael Wagner, Annika Spottke, Matthias Schmid, Sandra Roeske, Christoph Laske, Matthias H. Munk, Robert Perneczky, Boris-Stephan Rauchmann, Katharina Buerger, Daniel Janowitz, Emrah Düzel, Wenzel Glanz, Frank Jessen, Ayda Rostamzadeh, Jens Wiltfang, Claudia Bartels, Ingo Kilimann, Anja Schneider, Klaus Fliessbach, Josef Priller, Eike Jakob Spruth, Julian Hellmann-Regen, Oliver Peters","doi":"10.1002/alz.14545","DOIUrl":null,"url":null,"abstract":"The beneficial effects of amyloid beta 1-38, or Aβ(1-38), on Alzheimer's disease (AD) progression in humans in vivo remain controversial. We investigated AD patients' cerebrospinal fluid (CSF) Aβ(1-38) and AD progression.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"22 1","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/alz.14545","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The beneficial effects of amyloid beta 1-38, or Aβ(1-38), on Alzheimer's disease (AD) progression in humans in vivo remain controversial. We investigated AD patients' cerebrospinal fluid (CSF) Aβ(1-38) and AD progression.
期刊介绍：
Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
